Abstract
Objectives: To determine the impact of rectal swabs (RSs) on infectious complications (IC) following prostate biopsy (PB). Methods: A retrospective cohort study was conducted including all patients subjected to PB between 2009 and 2013. Group B consisted of patients with a RS and group A of patients without. RS reported the presence of gram-positive or negative germs, sensitive or resistant to ciprofloxacin. Antimicrobial prophylaxis was adjusted to the result. Frequency of IC in each group was determined. Results: Group B had 548 (47.20%) patients and group A 613 (52.80%). From group B, 250 (45.62%) of the RSs showed fluoroquinolone (FQ)-resistant germs. Forty nine (16.44%) patients with sensitive germs vs. 147 (59.51%) with resistant germs had a history of previous FQ treatment (p < 0.0001). IC were observed in 33 (5.49%) patients from group A and in 7 (1.28%) patients from group B (p < 0.0001), requiring hospitalization in 4.99 vs. 1.28%, respectively. IC and hospital admissions were reduced in 76.68 and 74.34%, respectively, following the implementation of RS. Conclusions: RS and targeted antibiotic prophylaxis prior to PB was associated with a significant reduction in IC and hospital admissions. Ceftriaxone could be an alternative in cases of known resistance. Past history of FQ treatment is associated with increased resistance.
Journal Section:
Editor's choice
References
1.
Loeb S, Vellekoop A, Ahmed HU, Catto J, Emberton M, Nam R, et al: Systematic review of complications of prostate biopsy. Eur Urol 2013;64:876-892.
[PubMed]
2.
Carignan A, Roussy JF, Lapointe V, Valiquette L, Sabbagh R, Pépin J: Increasing risk of infectious complications after transrectal ultrasound-guided prostate biopsies: time to reassess antimicrobial prophylaxis? Eur Urol 2012;62:453-459.
[PubMed]
3.
Aron M, Rajeev TP, Gupta NP: Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study. BJU Int 2000;85:682-685.
[PubMed]
4.
Zani EL, Clark OA, Rodrigues Netto N Jr: Antibiotic prophylaxis for transrectal prostate biopsy. Cochrane Database Syst Rev 2011;5:CD006576.
[PubMed]
5.
Wagenlehner FM, van Oostrum E, Tenke P, Tandogdu Z, Çek M, Grabe M, et al: Infective complications after prostate biopsy: outcome of the global prevalence study of infections in urology (GPIU) 2010 and 2011, a prospective multinational multicentre prostate biopsy study. Eur Urol 2013;63:521-527.
[PubMed]
6.
Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al: Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013;41:580-637.
[PubMed]
7.
Smyth LG, Mulvin DW: Antibiotic prophylaxis for transrectal ultrasound biopsy of the prostate in Ireland. Ir J Med Sci 2012;181:33-35.
[PubMed]
8.
Briffaux R, Coloby P, Bruyere F, Ouaki F, Pires C, Doré B, Irani J: One preoperative dose randomized against 3-day antibiotic prophylaxis for transrectal ultrasonography-guided prostate biopsy. BJU Int 2009;103:1069-1073; discussion 1073.
[PubMed]
9.
Bootsma AM, Laguna Pes MP, Geerlings SE, Goossens A: Antibiotic prophylaxis in urologic procedures: a systematic review. Eur Urol 2008;54:1270-1286.
[PubMed]
10.
Carmignani L, Picozzi S, Spinelli M, Di Pierro S, Mombelli G, Negri E, et al: Bacterial sepsis following prostatic biopsy. Int Urol Nephrol 2012;44:1055-1063.
[PubMed]
11.
Simsir A, Kismali E, Mammadov R, Gunaydin G, Cal C: Is it possible to predict sepsis, the most serious complication in prostate biopsy? Urol Int 2010;84:395-399.
[PubMed]
12.
de Jesus CM, Corrêa LA, Padovani CR: Complications and risk factors in transrectal ultrasound-guided prostate biopsies. Sao Paulo Med J 2006;124:198-202.
[PubMed]
13.
Kakehi Y, Naito S; Japanese Urological Association: Complication rates of ultrasound-guided prostate biopsy: a nation-wide survey in Japan. Int J Urol 2008;15:319-321.
[PubMed]
14.
Zaytoun OM, Vargo EH, Rajan R, Berglund R, Gordon S, Jones JS: Emergence of fluoroquinolone-resistant Escherichia coli as cause of postprostate biopsy infection: implications for prophylaxis and treatment. Urology 2011;77:1035-1041.
[PubMed]
15.
Castelblanco D, Jaramillo FG, Ordoñez CGT: Análisis retrospectivo de las biopsias de próstata realizadas en la Clínica de Próstata del Hospital universitario Fundación santa Fe de Bogotá. Urol Colomb 2011;20:27-33.
16.
Agresott-Guerra WA, Shek-Padilla ÁH, Quiroga-Matamoros W, Citarella-Otero DA: Biopsia transrectal de próstata guiada por ecografía con 12 muestras de la zona periférica y muestras de la zona centro transicional en rebiopsias para el diagnóstico de cáncer de próstata. Revista Urología Colombiana (Internet). 2011. http://www.redalyc.org/articulo.oa?id=149122333004 (February 11, 2016).
17.
Dodds PR, Boucher JD, Shield DE, Bernie JE, Batter SJ, Serels SR, et al: Are complications of transrectal ultrasound-guided biopsies of the prostate gland increasing? Conn Med 2011;75:453-457.
[PubMed]
18.
Nam RK, Saskin R, Lee Y, Liu Y, Law C, Klotz LH, et al: Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 2013;189(1 suppl):S12-S17; discussion S17-S18.
[PubMed]
19.
Feliciano J, Teper E, Ferrandino M, Macchia RJ, Blank W, Grunberger I, Colon I: The incidence of fluoroquinolone resistant infections after prostate biopsy - are fluoroquinolones still effective prophylaxis? J Urol 2008;179:952-955; discussion 955.
[PubMed]
20.
Otrock ZK, Oghlakian GO, Salamoun MM, Haddad M, Bizri AR: Incidence of urinary tract infection following transrectal ultrasound guided prostate biopsy at a tertiary-care medical center in Lebanon. Infect Control Hosp Epidemiol 2004;25:873-877.
[PubMed]
21.
Siriboon S, Tiengrim S, Taweemongkongsup T, Thamlikitkul V, Chayakulkeeree M: Prevalence of antibiotic resistance in fecal flora of patients undergoing transrectal ultrasound-guided prostate biopsy in Thailand. Urol Int 2012;88:187-193.
[PubMed]
22.
Gil-Vernet Sedo JM, Alvarez-Vijande García R: Effect of intrarectal povidone-iodine in the incidence of infectious complications after transrectal prostatic biopsy. Arch Esp Urol 2012;65:463-466.
[PubMed]
23.
Abughosh Z, Margolick J, Goldenberg SL, Taylor SA, Afshar K, Bell R, et al: A prospective randomized trial of povidone-iodine prophylactic cleansing of the rectum before transrectal ultrasound guided prostate biopsy. J Urol 2013;189:1326-1331.
[PubMed]
24.
Chan ES, Lo K, Ng C, Hou S, Yip SK: Randomized controlled trial of antibiotic prophylaxis regimens for transrectal ultrasound-guided prostate biopsy. Chin Med J (Engl) 2012;125:2432-2435.
[PubMed]
25.
Madden T, Doble A, Aliyu SH, Neal DE: Infective complications after transrectal ultrasound-guided prostate biopsy following a new protocol for antibiotic prophylaxis aimed at reducing hospital-acquired infections. BJU Int 2011;108:1597-1602.
[PubMed]
26.
Pace G, Carmignani L, Marenghi C, Mombelli G, Bozzini G: Cephalosporins periprostatic injection: are really effective on infections following prostate biopsy? Int Urol Nephrol 2012;44:1065-1070.
[PubMed]
27.
Gottesman T, Yossepowich O, Harari-Schwartz O, Tsivian A, Idler J, Dan M: The value of rectal cultures in treatment of sepsis following post-transrectal ultrasound-guided prostate biopsy. Urol Int 2015;95:177-182.
[PubMed]
28.
Duplessis CA, Bavaro M, Simons MP, Marguet C, Santomauro M, Auge B, et al: Rectal cultures before transrectal ultrasound-guided prostate biopsy reduce post-prostatic biopsy infection rates. Urology 2012;79:556-561.
[PubMed]
29.
Taylor AK, Zembower TR, Nadler RB, Scheetz MH, Cashy JP, Bowen D, et al: Targeted antimicrobial prophylaxis using rectal swab cultures in men undergoing transrectal ultrasound guided prostate biopsy is associated with reduced incidence of postoperative infectious complications and cost of care. J Urol 2012;187:1275-1279.
[PubMed]
30.
Liss MA, Kim W, Moskowitz D, Szabo RJ: Comparative effectiveness of targeted vs empirical antibiotic prophylaxis to prevent sepsis from transrectal prostate biopsy: a retrospective analysis. J Urol 2015;194:397-402.
[PubMed]
31.
Hanna MY, Tremlett C, Josan G, Eltom A, Mills R, Rochester M, Livermore DM: Prevalence of ciprofloxacin-resistant Enterobacteriaceae in the intestinal flora of patients undergoing transrectal prostate biopsy in Norwich, UK. BJU Int 2015;116:131-134.
[PubMed]
32.
Taylor S, Margolick J, Abughosh Z, Goldenberg SL, Lange D, Bowie WR, et al: Ciprofloxacin resistance in the faecal carriage of patients undergoing transrectal ultrasound guided prostate biopsy. BJU Int 2013;111:946-953.
[PubMed]
33.
Schellhammer PF, Schaeffer A: Infection associated with transrectal ultrasound guided biopsies of the prostate. PCRI Insights 2011;14:24-25.
34.
Chang Q, Wang W, Regev-Yochay G, Lipsitch M, Hanage WP: Antibiotics in agriculture and the risk to human health: how worried should we be? Evol Appl 2015;8:240-247.
[PubMed]
35.
Steensels D, Slabbaert K, De Wever L, Vermeersch P, Van Poppel H, Verhaegen J: Fluoroquinolone-resistant E. coli in intestinal flora of patients undergoing transrectal ultrasound-guided prostate biopsy - should we reassess our practices for antibiotic prophylaxis? Clin Microbiol Infect 2012;18:575-581.
[PubMed]
36.
Cussans A, Somani BK, Basarab A, Dudderidge TJ: The role of targeted prophylactic antimicrobial therapy before transrectal ultrasonography-guided prostate biopsy in reducing infection rates: a systematic review. BJU Int 2016;117:725-731.
[PubMed]
© 2016 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2016
You do not currently have access to this content.
